PICATO (Ingenol mebutate 0.015% and 0.05% gels): A novel treatment for actinic keratosis

SKINmed

Volumn 11, Issue 2, 2013, Pages 111-115

  Abramovits, William ^a,b,c   Oquendo, Marcial ^c   Vincent, Kimberly D ^d   Gupta, Aditya K ^e  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Dermatology Treatment and Research Center   (United States)

^d Belle Meade Dermatology   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 INGENYL ANGELATE; 3-INGENYL ANGELATE; DERMATOLOGICAL AGENT; DITERPENE;

ACTINIC KERATOSIS; ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GEL; HUMAN; INTRADERMAL DRUG ADMINISTRATION; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; UNITED STATES;

ADMINISTRATION, CUTANEOUS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; GELS; HUMANS; KERATOSIS, ACTINIC; SKIN NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MLCS; MLOWN;

EID: 84879977880     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Note

References (17)

1. Skin Cancer Foundation. Skin Cancer Information. http://www.skincancer.org/.
2. Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Therapy Lett. Feb 2012;17(2):1-3.
3. Weedon D, Chick J. Home treatment of basal cell carcinoma. Med J Aust. Jun 12 1976;1(24):928.
4. LEO Pharma announces that Picato® (ingenol mebutate) gel has been approved by US FDA for once-daily, 2 or 3 day treatment of actinic keratoses. 2012. http://www.leo-pharma.us/Home/News.aspx.
5. LEO PHARMA Inc. Picato® [Package Insert]. Parsippany, NJ 07054, USA. 2012.
6. Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. Apr 15 2004;64(8):2833-9.
7. Serova M, Ghoul A, Benhadji KA, et al. Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. Mol Cancer Ther. Apr 2008;7(4):915-22.
8. Tomas D. [Apoptosis, UV-radiation, precancerosis and skin tumors]. Acta Med Croatica. Oct 2009; 63. Suppl 2:53-8.
9. Zibert BM, Grue-Soerensen G, Møller K, Stahlhut M, Eriksson AH, et al. Ingenol Mebutate Penetrates Reconstructed Human Skin In A Gradient Dependent Manner And Clears Subclinical Skin Cancer. J Am Acad Dermatol. 2012; 66(4, Suppl 1): AB152.
10. Challacombe JMSA, Parsons PG, Jones B, Hampson P, Kavanagh D, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177(11):8123-32.
11. Li LSS, Lee A, Garfield SH, Maloney DJ, Ambudkar SV, et al. Cancer Res 477. 2010;70:4509-19.
12. Stahlhut MLJ, Bertelsen M, Worm J, Hampson P, Chahal H, Zibert J. Ingenol mebutate initiates multiple specific cell death pathways in human cancer cells. J Am Acad Dermatol. 2012;66(4, Suppl 1): AB152.
13. Fecker LFSE, Braun FK, Rodust PM, Schwarz C, Kohler A, et al. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J Invest Dermatol. 2010;130(8):2098-109.
14. Cozzi SJ OS, James C, Rebel HG, de Gruijl FR, Ferguson B, et al. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2011;doi:10.1038/jid.2011.418.
15. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. Mar 15 2012;366(11):1010-9.
16. Schmieder G. Multicenter, open-label, dose-area escalation, cohort study to evaluate the safety and tolerability of PEP005 (ingenol mebutate) gel 0.05% applied for two consecutive days to treatment area(s) of up to a total of 100cm2 in patients with actinic keratoses. Poster 2010. Annual AAD Meeting. 2010.
17. LEO Pharma. A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp. 2012. http://clinicaltrials.gov/ct2/show/study/NCT01541553.